Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9101)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2016 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i23/5384.htm |
| Number | Citing Articles |
| 1 |
Ai Shen, Miao Liu, Daofeng Zheng, Qingsong Chen, Zhongjun Wu. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2020; 44(2): 142 doi: 10.1016/j.clinre.2019.06.012
|
| 2 |
Ao Huang, Xin-Rong Yang, Wen-Yuan Chung, Ashley R. Dennison, Jian Zhou. Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00264-x
|
| 3 |
Mona A. Abu El-Makarem, Mariana F. Kamel, Ahmed A. Mohamed, Hisham A. Ali, Mahmoud R. Mohamed, Alaa El-Deen M. Mohamed, Ahmed M. El-Said, Mahmoud G. Ameen, Alshymaa A. Hassnine, Hatem A. Hassan, Gianfranco D. Alpini. Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor. PLOS ONE 2022; 17(11): e0277266 doi: 10.1371/journal.pone.0277266
|
| 4 |
Weichun Pan, Feina Gu, Xinyu Yan, Jianghui Huang, Huabin Liao, Fuge Niu. Biomacromolecular carriers based hydrophobic natural products for potential cancer therapy. International Journal of Biological Macromolecules 2024; 269: 132274 doi: 10.1016/j.ijbiomac.2024.132274
|
| 5 |
Philipp Heumann, Andreas Albert, Karsten Gülow, Deniz Tümen, Martina Müller, Arne Kandulski. Insights in Molecular Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(10): 1831 doi: 10.3390/cancers16101831
|
| 6 |
Yan-Yan Wang, Bao-Cai Xing. Author's reply: Comment on ``Effect of vessels that encapsulate tumor clusters (VETC) and different stages of hepatocellular carcinoma after hepatectomy''. Digestive and Liver Disease 2023; 55(10): 1441 doi: 10.1016/j.dld.2023.06.031
|
| 7 |
Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang, Zhi-yong Huang. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1202039
|
| 8 |
Yu Tian, Meng Zhang, Li-xia Liu, Zi-chao Wang, Bin Liu, Youcai Huang, Xiaoling Wang, Yun-zhi Ling, Furong Wang, Xiaoqiang Feng, Yanyang Tu. Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1400744
|
| 9 |
Faryal Mehwish Awan, Anam Naz, Ayesha Obaid, Aqsa Ikram, Amjad Ali, Jamil Ahmad, Abdul Khaliq Naveed, Hussnain Ahmed Janjua. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11943-1
|
| 10 |
Xiao-Dong Zhu, Hui-Chuan Sun. Emerging agents and regimens for hepatocellular carcinoma. Journal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-019-0794-6
|
| 11 |
Kongying Lin, Fuqun Wei, Qizhen Huang, Zisen Lai, Jinyu Zhang, Qingjing Chen, Yabin Jiang, Jie Kong, Shichuan Tang, Jianhuai Lin, Yufeng Chen, Jinhong Chen, Yongyi Zeng. Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. Journal of Hepatocellular Carcinoma 2022; : 127 doi: 10.2147/JHC.S352480
|
| 12 |
Wenli Liu, Yuqin Wang, Lijie Xia, Jinyao Li. Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer. Nutrients 2024; 16(6): 797 doi: 10.3390/nu16060797
|
| 13 |
Ganesh Manudhane, Ria Mehta, Shamshersingh Chauhan, Maharudra Kumbhar. Management of Acute Coronary Syndrome With a Bleeding Intra-Tumoral Hepatocellular Carcinoma: A Case Report. Cureus 2022; doi: 10.7759/cureus.27653
|
| 14 |
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis, Ernesto Claar. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?. Cancers 2023; 15(11): 2950 doi: 10.3390/cancers15112950
|
| 15 |
Valentina Zanuso, Lorenza Rimassa, Chiara Braconi. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology 2023; doi: 10.1097/HEP.0000000000000572
|
| 16 |
Wenkai Ni, Shiqing Zhang, Bo Jiang, Runzhou Ni, Mingbing Xiao, Cuihua Lu, Jinxia Liu, Lishuai Qu, Hongbing Ni, Wenwen Zhang, Pinghong Zhou. Identification of cancer-related gene network in hepatocellular carcinoma by combined bioinformatic approach and experimental validation. Pathology - Research and Practice 2019; 215(6): 152428 doi: 10.1016/j.prp.2019.04.020
|
| 17 |
Wang Gu, Zhong Tong. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. Journal of International Medical Research 2020; 48(8) doi: 10.1177/0300060520946872
|
| 18 |
Yuanpeng Bao, Song Xu, Junjing Zhou, Chongyong Zhao, Saimin Dai, Yong Zhang, Min Rao. Exosomal miR‐93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway. Journal of Biochemical and Molecular Toxicology 2024; 38(3) doi: 10.1002/jbt.23666
|
| 19 |
John R. Bergquist, Amy Y. Li, Christopher S. Javadi, Byrne Lee, Jeffrey A. Norton, George A. Poultsides, Monica M. Dua, Brendan C. Visser. Regional lymph node sampling in hepatoma resection: insight into prognosis. HPB 2021; 23(9): 1360 doi: 10.1016/j.hpb.2021.01.006
|
| 20 |
Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng. Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion. Current Oncology 2023; 30(12): 10134 doi: 10.3390/curroncol30120737
|
| 21 |
Kuan-Chun Hsueh, Cheng-Chun Lee, Pi-Teh Huang, Chih-Yu Liang, Shun-Fa Yang. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. Current Oncology 2023; 30(3): 3206 doi: 10.3390/curroncol30030243
|
| 22 |
Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2023; 149(12): 10505 doi: 10.1007/s00432-023-04874-0
|
| 23 |
Feng Che, Yi Wei, Qing Xu, Qian Li, Tong Zhang, Li-Ye Wang, Man Li, Fang Yuan, Bin Song. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma. Abdominal Radiology 2024; 49(9): 3024 doi: 10.1007/s00261-024-04190-2
|
| 24 |
Hiroto Matsui Matsui, Shoichi Hazama, Masao Nakajima, Ming Xu, Satoshi Matsukuma, Yukio Tokumitsu, Yoshitaro Shindo, Shinobu Tomochika, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Masaaki Oka, Hiroaki Nagano. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial. Cancer Immunology, Immunotherapy 2021; 70(4): 945 doi: 10.1007/s00262-020-02737-y
|
| 25 |
Yuqin Wang, Jinyao Li, Lijie Xia. Plant-derived natural products and combination therapy in liver cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1116532
|
| 26 |
Yifei Tan, Qing Xu, Zhenru Wu, Wei Zhang, Bo Li, Bohan Zhang, Xi Xu, Bo Zhang, Ke Yan, Jiulin Song, Tao Lv, Jian Yang, Li Jiang, Yujun Shi, Jiayin Yang, Lunan Yan. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.783335
|
| 27 |
Shenyu Zhang, Guibin Yang, Ruipeng Song, Wei Wang, Fanzheng Meng, Dalong Yin, Jiabei Wang, Shugeng Zhang, Wei Cai, Yao Liu, Dayong Luo, Jizhou Wang, Lianxin Liu. Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience. Therapeutic Advances in Medical Oncology 2024; 16 doi: 10.1177/17588359241258394
|
| 28 |
Masataka Amisaki, Hiroaki Saito, Naruo Tokuyasu, Teruhisa Sakamoto, Soichiro Honjo, Yoshiyuki Fujiwara. Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2018; 17(4): 323 doi: 10.1016/j.hbpd.2018.03.016
|
| 29 |
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02280-9
|
| 30 |
Ezgi AVANAZ, Dinç DİNÇER, Ali AVANAZ, Gülsüm Özlem ELPEK, Esra ÇOBANKENT AYTEKİN, Erdem AYIK. Demographic, Clinical and Treatment Characteristics of Patients with Hepatocellular Cancer: 10 Years of Experience of a Single Center. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 2023; 10(3): 186 doi: 10.47572/muskutd.1352879
|
| 31 |
Qingli Li, Tianqiang Song. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.633033
|
| 32 |
Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Frontiers of Medicine 2021; 15(2): 155 doi: 10.1007/s11684-021-0848-3
|
| 33 |
Jeng-Shiun Du, Shih-Hsien Hsu, Shen-Nien Wang. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(7): 1422 doi: 10.3390/cancers16071422
|
| 34 |
Quanyou Gong, Zhaoxia Qin, Fangli Hou. Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation. Oncology Letters 2017; doi: 10.3892/ol.2017.7174
|
| 35 |
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. Journal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
|
| 36 |
Ana I. Álvarez-Mercado, Albert Caballeria-Casals, Carlos Rojano-Alfonso, Jesús Chávez-Reyes, Marc Micó-Carnero, Alfredo Sanchez-Gonzalez, Araní Casillas-Ramírez, Jordi Gracia-Sancho, Carmen Peralta. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 2021; 9(9): 1158 doi: 10.3390/biomedicines9091158
|
| 37 |
Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1098958
|
| 38 |
Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery 2023; 15(1): 19-31 doi: 10.4240/wjgs.v15.i1.19
|